Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate), Diabetic Kidney Disease
Conditions
Brief summary
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Interventions
DIAGNOSTIC_TESTKidneyIntelX
KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
Sponsors
Renalytix AI, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
23 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 23 years of age or older. * Clinical history of confirmed type 2 diabetes. * Evidence of DKD Stages 1-3: * Baseline eGFR of 30-59 ml/min/1.73m2 (confirmed 3 months apart with at least one value within 1 year prior to enrollment) * Individuals with eGFR ≥60 ml/min/1.73m2 and albuminuria (UACR ≥30mg/g) * All patients will have a HbA1c, eGFR, urine albumin and urine creatinine, eGFR, available from within 12 months of enrollment (to be obtained if not clinically available prior). * The subject must be able to comprehend and sign an approved informed consent form and other applicable study documents.
Exclusion criteria
* Patients with eGFR \<30 or ≥ 60 ml/min/1.73m2 without albuminuria. * Patients with ESRD or on renal recovery treatments at time of enrollment. * Patients who are pregnant at the time of enrollment. * Patients who are currently hospitalized. * Patients who are currently on Enbrel.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood pressure | 12 Months | Proportion (target: 20% increase from prior measurements) of visits in which each participant achieves target blood pressure of \<140/90 mmHg (as per the NKF CKD management guidelines). |
| HbA1c | 12 Months | Proportion (target: 20% increase) of patients that achieve individualized target of HbA1c. |
| ACEi/ARB | 12 Months | Proportion (target: 20% increase) of patients recently treated with statins and or angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers. |
| SGLT2/ GLP1 | 12 Months | Proportion (target: 20% increase) of patients recently treated with SGLT2 inhibitors or GLP1 agonists. |
| Urine albumin to creatinine ratio | 12 Months | In those with baseline albuminuria, proportion (target: 20%) of patients achieving a 30% decrease in their urine albumin to creatinine ratio from averaged pre-enrollment values to average post-enrollment values through 1 year. |
| Referrals | 12 Months | Proportion (target: 20% increase) of patients referred/managed by a dietician, diabetologist, or nephrologist. |
Countries
United States
Outcome results
None listed